Document Detail


Antitumor efficiency of novel fluoro-substituted 6-amino-2-phenylbenzothiazole hydrochloride salts in vitro and in vivo.
MedLine Citation:
PMID:  16894403     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The purpose of this study was to investigate antitumor activity of novel fluoro-substituted 6-amino-2-phenylbenzothiazole hydrochloride salts in vitro and in vivo. A novel series of hydrochloride or dihydrochloride salts of the novel 2-(fluoro-substituted phenyl)-6-aminobenzothiazoles (5-7) have been prepared in multistep synthesis starting from 3- or 4-fluorobenzaldehydes and 2-amino-5-nitrothiophenol and evaluated for their antiproliferative activity against human cervical (HeLa), breast (MCF-7), colon (CaCO-2), and laryngeal (Hep-2) carcinomas and against fibroblast cell lines (WI-38). Also, antitumor activity of these compounds was evaluated in vitro and in vivo against murine melanoma (B16-F10), fibrosarcoma (FsaR), and squamous cell carcinoma (SCCVII). The tested compounds were found to exert good cytotoxic activity in vitro. The cytotoxic effect was selective, cell specific, and dose dependent, between 33 microM for MCF-7 and 110 microM for WI-38. Benzothiazoles reduced de novo protein and DNA synthesis up to 75%. All examined benzothiazoles had significant antitumor activity in vivo against melanoma B16-F10, fibrosarcoma, and squamous cell carcinoma. The best therapeutic results were achieved when therapy started 7 days after tumor cell implantation and when benzothiazoles were given repeatedly five times every 2 days, i.e., on day 7, 9, 11, 13, and 15 after transplantation of tumor cells.
Authors:
R Stojkovic; G Karminski-Zamola; L Racane; V Tralic-Kulenovic; L Glavas-Obrovac; S Ivankovic; M Radacic
Related Documents :
8576923 - Antitumor 2-(aminocarbonyl)-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)- hydrazines.
15635233 - Preparation of 2-pyridone-containing tricyclic alkaloid derivatives as potential inhibi...
16037823 - Combination effect of oncolytic adenovirotherapy and trail gene therapy in syngeneic mu...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Methods and findings in experimental and clinical pharmacology     Volume:  28     ISSN:  0379-0355     ISO Abbreviation:  Methods Find Exp Clin Pharmacol     Publication Date:    2006 Jul-Aug
Date Detail:
Created Date:  2006-08-08     Completed Date:  2006-11-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7909595     Medline TA:  Methods Find Exp Clin Pharmacol     Country:  Spain    
Other Details:
Languages:  eng     Pagination:  347-54     Citation Subset:  IM    
Affiliation:
Division of Molecular Medicine, Rudjer Boskovic Institute, Bijenicka, Zagreb, Croatia. stojkov@irb.hr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Agents / chemical synthesis*,  pharmacology*
Carcinoma, Squamous Cell / drug therapy,  pathology
Cell Line, Tumor
Cell Proliferation / drug effects
Cell Survival
DNA, Neoplasm / biosynthesis
Drug Screening Assays, Antitumor
Fibroblasts / drug effects
Fibrosarcoma / drug therapy,  pathology
Humans
Indicators and Reagents
Melanoma, Experimental / drug therapy,  pathology
Mice
Mice, Inbred C3H
Mice, Inbred C57BL
Neoplasm Proteins / biosynthesis
Neoplasm Transplantation
RNA, Neoplasm / biosynthesis
Thiazoles / chemical synthesis*,  pharmacology
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/DNA, Neoplasm; 0/Indicators and Reagents; 0/Neoplasm Proteins; 0/RNA, Neoplasm; 0/Thiazoles

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Links between Alzheimer's disease and diabetes.
Next Document:  Human erythrocytes are not suitable for determination of intravascular volume of perfused rat liver.